bioRxiv · 10.1101/2024.10.15.618096
Aβ-targeting synNotch Receptor for Alzheimer's Disease: Expanding Applications to Extracellular Protein Aggregates
Abstract
The synthetic Notch receptor (synNotch) system is a versatile platform that induces gene transcription in response to extracellular signals. However, its application has been largely confined to membrane-bound targets due to specific activation requirements. Whether synNotch can also target extracellular protein aggregates, such as amyloid beta (A{beta}) in Alzheimers disease (AD), is unclear. To address this, we engineered an A{beta}-targeting synNotch receptor controlling the production of chimeric human-mouse versions of Lecanemab (Leqembi(R)) or Aducanumab (Aduhelm(R)), both FDA-approved antibodies for AD. We demonstrate that NIH 3T3 cells expressing this synNotch system detect and respond to extracellular A{beta} aggregates by synthesizing and secreting Aducanumab or Lecanemab. These findings broaden the potential applications of synNotch, extending its targets beyond membrane-bound proteins to extracellular protein aggregates, providing obvious benefits to research in this scientific arena.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Bergo, N. J., Lee, S., Siebrand, C. J., Andersen, J., Walton, C. C.. 2024-10-17. Aβ-targeting synNotch Receptor for Alzheimer's Disease: Expanding Applications to Extracellular Protein Aggregates. https://doi.org/10.1101/2024.10.15.618096
Cite the original work for its findings. Save a collection to share your selection of sources.